Novel p53 therapies for head and neck cancer
Inactivation of the tumor suppressor p53 is the predominant pathogenetic event in head and neck squamous cell carcinoma (HNSCC). The p53 pathway in HNSCC can be compromised through multiple mechanisms including gene mutations, hyperactivation of endogenous negative p53 regulators and by the human pa...
Main Authors: | Mario R. Castellanos, Quintin Pan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2016-06-01
|
Series: | World Journal of Otorhinolaryngology-Head and Neck Surgery |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2095881116300142 |
Similar Items
-
Human papillomavirus, p16 and p53 expression associated with survival of head and neck cancer
by: Haugen Thomas H, et al.
Published: (2010-02-01) -
p53 Modulates Radiosensitivity in Head and Neck Cancers—From Classic to Future Horizons
by: Camil Ciprian Mireștean, et al.
Published: (2022-12-01) -
The p53-reactivating small molecule RITA induces senescence in head and neck cancer cells.
by: Hui-Ching Chuang, et al.
Published: (2014-01-01) -
Expert consensus on the clinical application of recombinant adenovirus human p53 for head and neck cancers
by: Yi Li, et al.
Published: (2021-11-01) -
Expression of p53 and bcl2 in squamous cell carcinoma of head and neck
by: Kanika Taneja, et al.
Published: (2016-09-01)